Pacira BioSciences vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Pacira BioSciences, Inc. (PCRX)

Q3 20265 Aug – 9 Oct 2026

▲2

Viatris buyout at $36.50 cash drives Pacira; EU deal adds growth

Viatris to acquire Pacira for $36.50/share in cash Viatris agreed to buy Pacira for $36.50 per share in cash, a 45% premium, sending the stock up 44% intraday. The deal is expected to close by end-2026, after which Pacira will be a wholly owned subsidiary and delisted. This sets a firm cash floor and is the dominant driver.
The buyout is the single biggest force moving PCRX, capping its price near the offer and driving the period's huge gain.
EU/UK EXPAREL licensing deal with Molteni Pacira signed an exclusive deal with Molteni to commercialize EXPAREL in the EU and UK, receiving an upfront payment, supply price, and royalties. First sales are expected in 2027. This expands long-term revenue potential, though it is now secondary to the buyout.
It shows a new growth avenue for Pacira's main product, supporting the value of the business being acquired.
Q2 profit swing and guidance cut after Iovera sale Pacira swung to a $4.65M profit and beat estimates, but cut full-year 2026 revenue guidance to $735–760M after selling its Iovera business to Zimmer Biomet. The guidance cut reflects lost revenue, while the profit and reimbursement wins for EXPAREL and ZILRETTA are positives.
It explains the underlying business performance and the reason for lower guidance, a key counterweight to the buyout news.

September 20265 Aug – 9 Oct 2026

▲2

Viatris buyout at $36.50 cash drives Pacira; EU deal adds growth

Viatris to acquire Pacira for $36.50/share in cash Viatris agreed to buy Pacira for $36.50 per share in cash, a 45% premium, sending the stock up 44% intraday. The deal is expected to close by end-2026, after which Pacira will be a wholly owned subsidiary and delisted. This sets a firm cash floor and is the dominant driver.
The buyout is the single biggest force moving PCRX, capping its price near the offer and driving the period's huge gain.
EU/UK EXPAREL licensing deal with Molteni Pacira signed an exclusive deal with Molteni to commercialize EXPAREL in the EU and UK, receiving an upfront payment, supply price, and royalties. First sales are expected in 2027. This expands long-term revenue potential, though it is now secondary to the buyout.
It shows a new growth avenue for Pacira's main product, supporting the value of the business being acquired.
Q2 profit swing and guidance cut after Iovera sale Pacira swung to a $4.65M profit and beat estimates, but cut full-year 2026 revenue guidance to $735–760M after selling its Iovera business to Zimmer Biomet. The guidance cut reflects lost revenue, while the profit and reimbursement wins for EXPAREL and ZILRETTA are positives.
It explains the underlying business performance and the reason for lower guidance, a key counterweight to the buyout news.

Latest5 Aug – 9 Oct 2026

▲2

Viatris buyout at $36.50 cash drives Pacira; EU deal adds growth

Viatris to acquire Pacira for $36.50/share in cash Viatris agreed to buy Pacira for $36.50 per share in cash, a 45% premium, sending the stock up 44% intraday. The deal is expected to close by end-2026, after which Pacira will be a wholly owned subsidiary and delisted. This sets a firm cash floor and is the dominant driver.
The buyout is the single biggest force moving PCRX, capping its price near the offer and driving the period's huge gain.
EU/UK EXPAREL licensing deal with Molteni Pacira signed an exclusive deal with Molteni to commercialize EXPAREL in the EU and UK, receiving an upfront payment, supply price, and royalties. First sales are expected in 2027. This expands long-term revenue potential, though it is now secondary to the buyout.
It shows a new growth avenue for Pacira's main product, supporting the value of the business being acquired.
Q2 profit swing and guidance cut after Iovera sale Pacira swung to a $4.65M profit and beat estimates, but cut full-year 2026 revenue guidance to $735–760M after selling its Iovera business to Zimmer Biomet. The guidance cut reflects lost revenue, while the profit and reimbursement wins for EXPAREL and ZILRETTA are positives.
It explains the underlying business performance and the reason for lower guidance, a key counterweight to the buyout news.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.